Journal
FRONTIERS IN ONCOLOGY
Volume 10, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2020.01538
Keywords
sorafenib; FLT3mutation; FLT3-V592; FLT3-N676; AML; TKI
Categories
Funding
- MD Anderson Cancer Centre Leukemia Support Grant (CCSG) [CA016672]
Ask authors/readers for more resources
The prognostics implications of patients with acute myeloid leukemia harboring non-canonicalFLT3is unknown. The use of tyrosine kinase inhibitors in this patient population has not been previously reported. We report successful targeted therapy against non-ITD, non-D835 driverFLT3alterations in two patient case studies with acute myeloid leukemia.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
